Los Angeles Capital Management’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-148,132
| Closed | -$809K | – | 2550 |
|
|
2025
Q4 | $809K | Sell |
148,132
-125,918
| -46% | -$669K | ﹤0.01% | 717 |
|
|
2025
Q3 | $1.46M | Sell |
274,050
-171,427
| -38% | -$727K | ﹤0.01% | 593 |
|
|
2025
Q2 | $1.53M | Buy |
445,477
+38,623
| +9% | +$123K | 0.01% | 515 |
|
|
2025
Q1 | $1.2M | Buy |
406,854
+121,175
| +42% | +$379K | 0.01% | 514 |
|
|
2024
Q4 | $871K | Buy |
285,679
+39,984
| +16% | +$116K | ﹤0.01% | 663 |
|
|
2024
Q3 | $627K | Buy |
+245,695
| New | +$744K | ﹤0.01% | 799 |
|
|
2022
Q2 | – | Sell |
-123,970
| Closed | -$357K | – | 1426 |
|
|
2022
Q1 | $357K | Buy |
123,970
+6,289
| +5% | +$16.3K | ﹤0.01% | 1174 |
|
|
2021
Q4 | $358K | Sell |
117,681
-25,260
| -18% | -$110K | ﹤0.01% | 1165 |
|
|
2021
Q3 | $1M | Buy |
142,941
+116,452
| +440% | +$872K | ﹤0.01% | 764 |
|
|
2021
Q2 | $243K | Buy |
26,489
+11,230
| +74% | +$114K | ﹤0.01% | 1447 |
|
|
2021
Q1 | $148K | Buy |
+15,259
| New | +$170K | ﹤0.01% | 1556 |
|
|
2020
Q3 | – | Sell |
-77,816
| Closed | -$812K | – | 1499 |
|
|
2020
Q2 | $812K | Buy |
77,816
+11,955
| +18% | +$124K | ﹤0.01% | 926 |
|
|
2020
Q1 | $556K | Buy |
65,861
+14,270
| +28% | +$139K | ﹤0.01% | 875 |
|
|
2019
Q4 | $451K | Buy |
51,591
+25,785
| +100% | +$213K | ﹤0.01% | 1040 |
|
|
2019
Q3 | $278K | Buy |
+25,806
| New | +$279K | ﹤0.01% | 1140 |
|
|
2019
Q2 | – | Sell |
-8,714
| Closed | -$338K | – | 1400 |
|
|
2019
Q1 | $338K | Buy |
+8,714
| New | +$266K | ﹤0.01% | 1173 |
|
|
2018
Q4 | – | Sell |
-13,339
| Closed | -$612K | – | 1356 |
|
|
2018
Q3 | $612K | Sell |
13,339
-37,060
| -74% | -$1.79M | ﹤0.01% | 1049 |
|
|
2018
Q2 | $2.98M | Buy |
50,399
+26,120
| +108% | +$1.51M | 0.02% | 597 |
|
|
2018
Q1 | $1.65M | Buy |
+24,279
| New | +$1.82M | 0.01% | 687 |
|
|
2017
Q4 | – | Sell |
-2,554
| Closed | -$306K | – | 1369 |
|
|
2017
Q3 | $306K | Buy |
+2,554
| New | +$238K | ﹤0.01% | 1148 |
|
|
2016
Q3 | – | Sell |
-26,794
| Closed | -$798K | – | 1266 |
|
|
2016
Q2 | $798K | Buy |
+26,794
| New | +$838K | 0.01% | 769 |
|
|
2015
Q3 | – | Sell |
-2,449
| Closed | -$286K | – | 1208 |
|
|
2015
Q2 | $286K | Sell |
2,449
-1,305
| -35% | -$236K | ﹤0.01% | 1075 |
|
|
2015
Q1 | $886K | Buy |
+3,754
| New | +$803K | 0.01% | 775 |
|
Other funds holding PBYI
ACA
VCM
VPM
Los Angeles Capital Management's PBYI Position: Q1 2026 in Review
Los Angeles Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 148,132 shares — an estimated $809K sold.
Los Angeles Capital Management first reported a position in PBYI in Q1 2015 and held it in 23 quarters. The position peaked at $2.98M in Q2 2018. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.
- Los Angeles Capital Management reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
- Los Angeles Capital Management sold 148,132 Puma Biotechnology shares in Q1 2026, an estimated $809K.
- Los Angeles Capital Management first reported a position in Puma Biotechnology in Q1 2015 and held it in 23 quarters.
- Los Angeles Capital Management's Puma Biotechnology position peaked at $2.98M in Q2 2018.
- 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.